Latest Conference Articles

Improving asthma management in schools not only benefits pediatric patients' health, but improves attendance rates.

Those with blood type B or AB are an estimated 5-fold less likely to be diagnosed with red meat allergy.

The condition was found to be linked in pediatric patients who already suffer from asthma, atopic dermatitis, or food allergies, and can lead to children developing allergic rhinitis.

New study results compound on previous evidence of an association between tick bites and red meat allergy.

Early allergen sensitization is associated with an increased risk of viral infections and the development of childhood asthma.

Alexia Beauregard, MS, RD, CSP, LD, explains how a food allergy specialist dietitian could make a life-saving difference in helping families understand food allergy.

As telehealth becomes more widely used, the role dietitians play in multidisciplinary teams for the treatment of allergy has increased.

The FDA previously approved DUPIXENT in the US for the treatment of adults with moderate-to-severe atopic dermatitis.

Patricia Dickson, M.D., discusses similarities between variations of MPS and the both the benefits and challenges of being a researcher in the rare disease community.

Hartmann Wellhoefer, M.D., head of medical affairs at Shire, sits down with RDR at the 14th Annual WORLDSymposium to discuss the company's recent data for lysosomal storage diseases.

With no real standard-of-care for Sanfilippo syndrome patients, Brian Bigger, Ph.D., discusses the sense of urgency he and his colleagues feel while researching.

BioMarin presented interim data at the 14th Annual WORLDSymposium in San Diego from a Phase 1/2 trial for BMN 250 in MPS IIIB.

ArmaGen reported full 52-week results from a Phase 2 proof-of-concept study with AGT-181 in MPS I.

Rare Disease Report sits down with Simon Heales, Ph.D., Professor of Clinical Chemistry at Great Ormond Street Children’s Hospital in London who discusses a potential link between Gaucher disease and Parkinson’s disease.

Sanofi Genzyme presented results from the Phase 1/2 trial, showing consistent safety data for the investigational avalglucosidase alfa in late-onset Pompe disease.

Amicus presented additional positive results from the company’s Phase 1/2 clinical study of ATB200/AT2221 in patients with Pompe disease in a late-breaker poster and a corresponding oral presentation.

Today at the WORLDSymposium in San Diego, Valerion Therapeutics presented initial results from the first cohort of its ongoing Phase 1/2 clinical study of VAL-1221 in patients with late-onset Pompe disease.

At the 14th Annual WORLDSymposium, interim data from two open-label studies were presented, exhibiting a 3-year survival estimate of 68% in infants with rapidly progressing LAL-D treated with sebelipase alfa.

The potential glaucoma and dry eye device administers 80% less topical treatment per dose.

The distractive spots floating through fields of vision may have finally met their match.

The multi-targeted inhibitor, a non-invasive eye drop, acts in a different way of treating the chronic disease.

The diagnostics of the disease is not only important for the initial evaluation, but also etiology and long-term management.

A review of over 13,000 newly-diagnosed DME patients found that about 75% received no treatment in the first 28 days since diagnosis.

Vision loss patients may be 3 times as likely to suffer from major depressive symptoms than the general population.

The biologic agent has shown efficacy in reducing asthma exacerbations and improving patient quality of life.

Attendees at MS Paris 2017 discussed the biggest unmet needs in treating multiple sclerosis.

Two consecutive CHEST studies showed combination therapy's expanding portfolio.

Telemedicine is more than just a trend in medicine – it's one of the most potent tools available to health systems and patients alike.